Abstract Presented at ASTRO 2018: Two Year Quality of Life Follow up on CivaString® Line Source for Prostate Brachytherapy reporting minimal side effects.

For Release at ASTRO 2018 From San Antonio, TX

RESEARCH TRIANGLE PARK, N.C.--CivaTech Oncology®—A new polymeric linear source shows significant improvement in prostate cancer patients. A team of expert physicians including Richard Stock MD, Jed Kaminetsky MD, Brian Moran MD, and Bradley Prestidge MD assessed the quality of life (QOL) of prostate cancer patients following the implant of CivaString®. Designed and manufactured by CivaTech Oncology, CivaString® is the only polymer encapsulated Pd-103 source with a unique linear radioactive distribution intended to provide a meaningful improvement on prostate brachytherapy seeds. Prostate brachytherapy is known to successfully treat prostate cancer with minimal side effects to patients. CivaString patients' two year outcomes for urinary, rectal and sexual function QOL are reported.

Poster presented October 21, 2018 at the 60th ASTRO Annual Meeting concluded "Patients tolerate Pd-103 line source brachytherapy with minimal side effects. Immediate symptoms from the procedure resolve quickly and patients routinely return to baseline function in less time than when treated with I-125."

Mild urinary symptoms have been reported following the implant of CivaString® as expected from LDR brachytherapy. However, these symptoms resolved prior to six month follow up with no statistically significant difference between baseline QOL and QOL at six months and up to 2 year follow up. No rectal toxicity was reported. Additionally, sexual function was maintained and men resumed normal activities more quickly compared to other radiation therapy procedures.

Therefore, physicians conclude that patients implanted with CivaString®, Pd-103 line source brachytherapy maintain their Quality of Life. Immediate symptoms from the procedure resolve quickly and patients return to their normal life without delay. The PSA tests demonstrate the expected decline indicating that patients are progression free.

About CivaString®:

The CivaString is the only LDR source made out of a flexible organic polymer in which the radioactive palladium material is embedded. It's unique construction delivers a much more uniform dose of radiation than traditional metal seeds, which can minimize the number of needles used and decrease the recovery time and side effects.

About CivaTech Oncology®:

CivaTech Oncology's products bring meaningful improvements to provide targeted radiation therapy. For more information, please visit www.civatechoncology.com.

ABOUT ASTRO

The American Society for Radiation Oncology (ASTRO) is the world's largest radiation oncology society, with more than 10,000 members who are physicians, nurses, biologists, physicists,

radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. The Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology • Biology • Physics, Practical Radiation Oncology and Advances in Radiation Oncology; developed and maintains an extensive patient website, RT Answers; and created the nonprofit foundation Radiation Oncology Institute. To learn more about ASTRO, visit astro.org or RTanswers.org, sign up to receive our news and follow us on our blog, Facebook and Twitter.

This news release contains additional and/or updated information from the study author(s).

CIVATECH ONCOLOGY

Release Summary

Drs. Richard Stock, Jed Kaminetsky, Brian Moran, and Bradley Prestidge conclude: patients tolerate CivaString®, the Pd-103 line source brachytherapy, with minimal side effects. Immediate symptoms from the procedure resolve quickly with this highly effective treatment.

For Clinical Study locations contact:

CivaTech Oncology Inc.®
Randy Harrison, 919-314-5515
National Sales Manager
rharrison@civatechoncology.com